Skip to contentA
Adaptimmune Therapeutics PLC
A
ADAPYAdaptimmune Therapeutics PLC Q4 2023 · 10-K
derived · Computed from the longer spans the company filed.
Revenue$231.00K$231.00Kderived−97.9% vs Q4 2022 Net Income-$47.92M-$47.92MderivedN/M vs Q4 2022 EPS, diluted—
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Adaptimmune Therapeutics PLC · CIK 1621227 · Engraved from SEC EDGAR
Not derived. Share counts vary by quarter.
Operating Incomederived-$49,856,000N/M Operating Cash Flowderived-$14,676,000N/M Free Cash Flowderived-$15,503,000N/M Margins · derivedOperating margin-21582.7%−21335.7 pt vs Q4 2022
Net margin-20743.3%−20478.1 pt vs Q4 2022
ended Dec 31, 2023 · filed Mar 6, 2024 · 66 d after period end